Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure2020 · 130 citations
2. 2Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments2017 · 231 citations
3. 3BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies2014 · 196 citations
4. 4Role of<i>ASXL1</i>and<i>TP53</i>mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes2015 · 78 citations
5. 5ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine2021 · 61 citations